Tesamorelin is the exception on this site. Every other compound here either has no label or has a label for a pen, but tesamorelin has three labels for a powder in a vial, each stating a daily dose, a diluent volume and the concentration that results. That makes it the one compound where "how many units" has a label-backed answer, and where the research-vial arithmetic can be laid beside a regulator's own version of the same sum. This page reports the three labels and the trials behind them, dated, and then works the 5 mg and 10 mg vials.
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone with a stabilising modification at its N-terminus, developed by Theratechnologies and sold as Egrifta. Medibact's Tesamorelin guide covers the molecule and its evidence; this page stays with figures. The peptide dosage section lists every compound's page. How tesamorelin compares with a ghrelin-receptor agonist, molecule for molecule, is on a side-by-side of tesamorelin and ipamorelin doses.
What the sources state
| Source | Kind | Figure | Date read |
|---|---|---|---|
| Egrifta SV label, Theratechnologies (revised 2/2024; DailyMed version published 2026-07-31) | Approved label | 1.4 mg subcutaneously once daily; 2 mg vial + 0.5 mL Sterile Water for Injection = 2 mg per 0.5 mL; 0.35 mL drawn, remainder discarded; 30 vials per box | 2026-09-18 |
| Egrifta WR label, Theratechnologies (revised 3/2025; DailyMed version published 2026-08-03) | Approved label | 1.28 mg subcutaneously once daily; 11.6 mg vial + 1.3 mL Bacteriostatic Water for Injection, USP = 8 mg/mL; 0.16 mL drawn; seven days per vial; four vials per box | 2026-09-18 |
| Egrifta, BLA 022505 (Drugs@FDA; approved 2010-11-10; 1 mg vials) | Approved product | 2 mg once daily from two 1 mg vials, the pivotal-trial regimen | 2026-09-18 |
| Falutz et al., NEJM 2007 (PMID 18057338) | Trial publication | 2 mg subcutaneously once daily for 26 weeks; visceral adipose tissue -15.2% vs +5.0% placebo | 2026-09-18 |
| NCT00123253 (412 participants) and NCT00608023 (263 participants, extension) | Trial protocol | The two phase 3 registrations behind the 2010 approval | 2026-09-18 |
| ClinicalTrials.gov search, "tesamorelin" | Registry | 24 records; daily doses of 1, 1.28, 1.4 and 2 mg; all subcutaneous, all once daily | 2026-09-18 |
| Clinic and vendor "protocol" pages | Commonly cited | 1 to 2 mg once daily; five days on, two off; three-month cycles with rest months | 2026-09-18 |
Three points stand out. The labelled dose has fallen over fifteen years, from 2 mg to 1.4 mg to 1.28 mg, with each new presentation. Every trial and every label is once daily and subcutaneous, without exception. The labels also name a single injection site, the abdomen, unlike the three-site GLP-1 labels; the detail is on where to inject tesamorelin. And the cycling patterns on clinic pages appear in none of the eight primary rows.
The label's own arithmetic
Egrifta SV reconstitutes a 2 mg vial in 0.5 mL, so the solution is 4 mg/mL, and the labelled 0.35 mL dose is 1.4 mg; on a U-100 syringe 0.35 mL is 35 units. Egrifta WR states its concentration directly, 8 mg/mL, and its 0.16 mL dose is 1.28 mg, or 16 units. Seven such doses are 1.12 mL, which is why the label describes one vial as a seven-day supply. The original product needed two 1 mg vials for its 2 mg dose. Those are the only unit figures on this page that come from a label rather than from arithmetic.
Units per dose at each research-vial size
Research-market tesamorelin is supplied in 5 mg and 10 mg vials. The table takes each at 1, 2 and 3 mL of water, states the concentration, and converts the four figures in the record, 1 mg (SMART), 1.28 mg (Egrifta WR), 1.4 mg (Egrifta SV) and 2 mg (Egrifta and the pivotal trial), into U-100 syringe units (100 units = 1 mL).
| Vial | Water added | Concentration | 1 mg | 1.28 mg | 1.4 mg | 2 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 20 | 25.6 | 28 | 40 |
| 5 mg | 2 mL | 2.5 mg/mL | 40 | 51.2 | 56 | 80 |
| 5 mg | 3 mL | 1.67 mg/mL | 60 | 76.8 | 84 | 120 (>1 syringe) |
| 10 mg | 1 mL | 10 mg/mL | 10 | 12.8 | 14 | 20 |
| 10 mg | 2 mL | 5 mg/mL | 20 | 25.6 | 28 | 40 |
| 10 mg | 3 mL | 3.33 mg/mL | 30 | 38.4 | 42 | 60 |
The 1.28 mg and 1.4 mg columns produce fractional units at most concentrations, which is a consequence of the labels being written for their own vial sizes rather than for these. A 5 mg vial at 5 mg/mL holds two and a half of the 2 mg amounts, and a 10 mg vial at the same concentration holds five. The tesamorelin reconstitution calculator works any combination entered. Water volume per vial size, the resulting concentration and the units for the labelled amounts are worked through on the tesamorelin reconstitution page.
What the figures omit
The labels attach a single indication, HIV-associated lipodystrophy in adults, and a set of monitoring and contraindication statements that belong to the finished product. The pivotal trial attaches a 26-week duration and a population defined by HIV and abdominal fat; the academic trials attach their own populations. The clinic pages attach cycles that no label or trial contains. A research vial attaches none of these, and the arithmetic above moves only the milligram figures. One registry record is worth a separate mention: NCT07481734, first posted 2026-03-19, proposes 2 mg daily and carries "Mock Study" in its title; it is reported here as it appears, and it is not evidence of anything. Whether any trial ran it in cycles, and what happened to visceral fat when it was stopped, is set out on the tesamorelin cycle page. No figure on this page is set by sex; what the trials enrolled, and the one study that reported women separately, are on growth-hormone peptide dosage for women.
Related pages
Sermorelin dosage reports the other growth-hormone-releasing peptide on this site, whose label was withdrawn, and the two are set side by side, with half-lives and molecules per milligram, in tesamorelin vs sermorelin. The tesamorelin and ipamorelin stack article covers the combination readers most often search alongside it, the unstudied pairing with a weekly GLP-1 drug is on tirzepatide with tesamorelin, the label-versus-no-label comparison with the growth hormone fragment is on tesamorelin against AOD-9604, the analogue that bypasses the pituitary altogether is set against it in tesamorelin and IGF-1 LR3 compared, and the peptide blend calculator works two-vial arithmetic. Storage after mixing is the store's subject: medibact.com's how to store peptides page covers it, and its how to reconstitute peptides page covers the general procedure. Why an eight-minute half-life still comes with a once-daily label schedule, set against ten other compounds, is the subject of half-lives against dosing schedules. Its pairing with MOTS-c, where the label's glucose warning meets a peptide studied for insulin sensitivity, is on tesamorelin with MOTS-c.
The insulin syringe units how-to explains the U-100 and U-40 scales and how a milligram figure becomes a syringe reading.
What this page does not do
This page reports what three labels, one pivotal trial, the registry and the public web state about tesamorelin dosing, each with its source and date, and converts the sourced figures into syringe units for the two research-vial sizes. It does not recommend an amount, a schedule or a cycle, and it does not extend the labels' indication to any other use. The label figures are reported for the products the labels cover; the tables are arithmetic, not a plan.
Sources and dates
Opened 2026-09-18: the Egrifta SV label on DailyMed (set id 3d783378-b02d-4f19-99dd-0fc91a042224, revised 2/2024) and the Egrifta WR label on DailyMed (set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, revised 3/2025); the Drugs@FDA record for BLA 022505 through the openFDA endpoint; PMID 18057338 (Falutz et al., NEJM 2007); NCT00123253, NCT00608023 and NCT07481734 on ClinicalTrials.gov, and the registry search for tesamorelin (24 records); and a read of clinic and vendor protocol pages for the figures in circulation. Corrections go to the contact page.